Polymyositis News

Patients with immune mediated inflammatory diseases are tested for COVID-19 at a 20% higher rate than the general population, according to data published in Arthritis Care & Research.

A number of approaches and therapies may be necessary to treat cutaneous dermatomyositis, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

The mean annual direct and indirect costs related to idiopathic inflammatory myopathies are three to five times higher than in the general population, and begin increasing 2 years before diagnosis, according to data from a Swedish registry.

Although immunosuppressives remain the cornerstone for managing underlying interstitial lung disease in connective tissue diseases, new drug approvals could help shift the treatment paradigm, according to data presented here.

A thorough physical exam and attention to a patient’s medical history are integral to differentiating dermatomyositis from cutaneous dermatomyositis with similar features, according to a presenter here.

Juvenile dermatomyositis challenges rheumatologists to accurately assess not only the skin but also pulmonary and cardiac function in making a diagnosis, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.

This past spring, two studies shed light on how some of the largest clinician organizations and publishers in rheumatology, including the American College of Rheumatology and EULAR, have failed to provide adequate training materials or clear guidelines when it comes to caring for patients of color.

Skin disease is more active than muscle disease in juvenile dermatomyositis and should be treated early and aggressively to limit its severity, according to a study.

Patients who received rheumatology care from nurse practitioners or physician assistants rated their overall experience similarly to those who saw a rheumatologist, according to survey data published in Arthritis Care & Research.

Intravenous immunoglobulin 10% in doses of 2 g/kg demonstrated significantly higher treatment response rates, compared with placebo, in patients with dermatomyositis, according to a speaker at the EULAR 2021 Congress.